menu
    • menu

    Company profile for Kowa Pharmaceuticals America

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Established in 2008, Kowa Pharmaceuticals, Inc., is committed to developing and delivering safe, effective solutions in the field of cardiometabolic therapeutics. We do this by maintaining high ethical and professional standards—and it all starts with people. By empowering our employees to live this mission, we can create a healthier vision for the future. Develop and commercialize safe, effective, and high-quality pharmaceu...
    Established in 2008, Kowa Pharmaceuticals, Inc., is committed to developing and delivering safe, effective solutions in the field of cardiometabolic therapeutics. We do this by maintaining high ethical and professional standards—and it all starts with people. By empowering our employees to live this mission, we can create a healthier vision for the future. Develop and commercialize safe, effective, and high-quality pharmaceutical products at a reasonable cost, their mission is to be customer focused and provide the highest level of customer support and service, conduct all business with honesty, professionalism, and integrity, etc.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Kowa Pharmaceuticals AmericaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    530 Industrial Park Boulevard Montgomery, AL 36117
    Telephone
    Telephone
    334.288.1288
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.kowapharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/kowapharmaceuticalsamericainc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Enforcement Report - Week of March 19, 2025
    Enforcement Report - Week of March 19, 2025

    19 Mar 2025

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-19-2025-87488.pdf

    FDA
    19 Mar 2025
    Share Share
    Nicox and Kowa Enter into Agreement for NCX 470
    Nicox and Kowa Enter into Agreement for NCX 470

    08 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/08/2825691/0/en/Nicox-and-Kowa-Enter-into-Agreement-for-NCX-470-Development-and-Commercialization-in-Japan.html

    GLOBENEWSWIRE
    08 Feb 2024
    Share Share
    Kowa Pharma to Publish PIII Data Supporting FDA Approval of SEGLENTIS
    Kowa Pharma to Publish PIII Data Supporting FDA Approval of SEGLENTIS

    19 Jul 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220715005473/en

    BUSINESSWIRE
    19 Jul 2022
    Share Share
    Kowa To Discontinue K-877 (Pemafibrate)
    Kowa To Discontinue K-877 (Pemafibrate) "Prominent" CVS Outcomes Study

    08 Apr 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/kowa-to-discontinue-k-877-pemafibrate-prominent-cardiovascular-outcomes-study-301520956.html

    PRNEWSWIRE
    08 Apr 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search